bevacizumab + irinotecan + fluorouracil + capecitabine

A combination therapy regimen consisting of the monoclonal antibody bevacizumab and a chemotherapy backbone of irinotecan and fluorouracil (modified FOLFIRI-3), followed by maintenance therapy with bevacizumab and capecitabine. Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis. Irinotecan is a cytotoxic agent that inhibits DNA topoisomerase I, leading to double-strand DNA breaks. Fluorouracil and its oral prodrug capecitabine are antimetabolites that inhibit thymidylate synthase, disrupting DNA synthesis. This specific sequential regimen was investigated in a Phase II clinical trial (NCT00405379) sponsored by Hôpital Jean Minjoz for the treatment of patients with previously untreated metastatic colorectal adenocarcinoma.

Other names

bevacizumab-Hopital Jean Minjoz-metastatic colorectal cancerbevacizumab + modified FOLFIRI-3 followed by bevacizumab + capecitabinebevacizumab + FOLFIRI-3